![Unable to 'align' with FDA, Regeneron, Sanofi pull application for Libtayo in cervical cancer days before decision date | Fierce Pharma Unable to 'align' with FDA, Regeneron, Sanofi pull application for Libtayo in cervical cancer days before decision date | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1643380645/libtayo.png/libtayo.png?VersionId=PMEgzDUYP4gZ0g8l62XHiIkOjMTfgKU7)
Unable to 'align' with FDA, Regeneron, Sanofi pull application for Libtayo in cervical cancer days before decision date | Fierce Pharma
![The office of Sanofi (China) Investment Co., Ltd. is pictured in Shanghai, China, 9 August 2013. Chinese authorities have launched an investigation Stock Photo - Alamy The office of Sanofi (China) Investment Co., Ltd. is pictured in Shanghai, China, 9 August 2013. Chinese authorities have launched an investigation Stock Photo - Alamy](https://c8.alamy.com/comp/W92HPE/the-office-of-sanofi-china-investment-co-ltd-is-pictured-in-shanghai-china-9-august-2013-chinese-authorities-have-launched-an-investigation-W92HPE.jpg)
The office of Sanofi (China) Investment Co., Ltd. is pictured in Shanghai, China, 9 August 2013. Chinese authorities have launched an investigation Stock Photo - Alamy
![ConAgra, Roche, Sanofi-Aventis and RadioShack Pull Advertisements from Fox News Channel's Glenn Beck | Color Of Change ConAgra, Roche, Sanofi-Aventis and RadioShack Pull Advertisements from Fox News Channel's Glenn Beck | Color Of Change](https://colorofchange.org/wp-content/uploads/2016/03/c8baa925948f8b2ed30c1554fc271029-1080x572.jpg)
ConAgra, Roche, Sanofi-Aventis and RadioShack Pull Advertisements from Fox News Channel's Glenn Beck | Color Of Change
![Sanofi's Dupixent, amid €10B sales push, posts positive data in chronic spontaneous urticaria | Fierce Pharma Sanofi's Dupixent, amid €10B sales push, posts positive data in chronic spontaneous urticaria | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1627569342/DupixentPackage.jpg/DupixentPackage.jpg?VersionId=ZwEoEpGTEXHLujNlPcOodUUrhktjOrAl)
Sanofi's Dupixent, amid €10B sales push, posts positive data in chronic spontaneous urticaria | Fierce Pharma
![Regeneron and Sanofi pull Libtayo's application for cervical cancer treatment | HealthCare Africa Magazine Regeneron and Sanofi pull Libtayo's application for cervical cancer treatment | HealthCare Africa Magazine](https://www.healthcareafrica.info/wp-content/uploads/2022/01/Libtayo1.jpg)